Clarivate Epidemiology’s coverage of spinal muscular atrophy (SMA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…
Clarivate Epidemiology’s coverage of genitourinary syndrome of menopause (GSM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, and Peru). We…
The number of prevalent cases of AD in the countries under study will increase by 43% over the 10-year forecast period, from 384,000 to 548,000. Of the countries considered in this analysis,…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the Asia-Pacific region. We report both the incidence and…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark, Finland,…
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…
Clarivate Epidemiology’s coverage of ischemic stroke (IS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of sepsis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Clarivate Epidemiology’s coverage of choroideremia (CHM) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of HIV/AIDS-related neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of herpes zoster (HZ) comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets. We report the incidence of HZ for each…
Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed…